VRCA); The deadline for the lead applicant is August 5, 2022

PHILADELPHIA CREAM, June 30, 2022 /PRNewswire/ — Shepherd Montague is investigating allegations of securities fraud on behalf of investors who purchased Verrica Pharmaceuticals, Inc. (“Verrica” ​​or the “Company”) (NASDAQ: VRCA) securities between May 28, 2021 and May 24, 2022 (the “Class Period”).

If you purchased Verrica securities during the Class Period, would like to discuss At Berger Montague investigation, or if you have any questions regarding your rights or interests, please contact the lawyers Andre Abramowitz at [email protected] or (215) 875-3015, or Michael Dell‘Angelo to [email protected] or (215) 875-3080 or visit: https://investigations.bergermontague.com/verrica-pharmaceuticals/

Whistleblowers: Anyone with non-public information about Verrica is encouraged to help confidentially. At Berger Montague survey or take advantage of the SEC Whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us.

In December 2020Verrica has submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA) seeking regulatory approval of VP-102 for the treatment of molluscum.

On September 20, 2021, Verrica announced receipt of a Complete Response Letter (CRL) due to deficiencies in a Verrica subcontractor facility. At this news, the Company’s share price fell. $1.00i.e. 8.3%, to close at $11.03 per share on September 21, 2021.

On May 24, 2022Verrica announced the receipt of another CRL regarding NDA VP-102, citing deficiencies identified during a general re-inspection of the contract manufacturing organization (CMO) that manufactures Verrica’s bulk solution drug.

At this news, the Company’s shares fell $3.55i.e. 63.8%, to close at $2.01 per share on May 25, 2022on an unusually high volume of transactions.

Shepherd Montaguewith offices at philadelphia cream, Minneapolis, washington d.c.and San Diegohas been a pioneer in securities class actions since its founding in 1970. Shepherd Montague has represented individual and institutional investors for over five decades and acts as lead counsel before courts across United States.

Andre Abramowitzsenior counsel
Shepherd Montague
(215) 875-3015
[email protected]

Michael Dell‘Angelo, executive shareholder
Shepherd Montague
(215) 875-3080
[email protected]

THE SOURCE Shepherd Montague

Karen J. Nelson